75 Billion Reasons To Own Google
Alphabet (Google’s parent) has significantly ramped up research and development spending in recent years. In 2022, Google spent about $39.5 billion on R&D, which jumped to $45.4 billion in 2023. This ~15% increase was driven largely by higher personnel costs (adding thousands of engineers) and one-time charges like office space consolidation.
R&D now represents roughly 15% of Google’s annual revenue, » Read more about: 75 Billion Reasons To Own Google »
Read More
Is This Buffett Stock Doomed?
With over 33 million subscribers as of 2024, Sirius XM seems like a company that has scaled and locked in a wide moat, but is there more to this Buffett stock than meets the eye.
After all, Buffett may be famous for making billions but he’s not immune to picking poor stocks from time to time.
» Read more about: Is This Buffett Stock Doomed? »
Read More
Buffett Has Sold For 7 Quarters In a Row, What Happens Next?
When it comes to investing, following the actions of top investors is a much smarter play than following their words. Take Warren Buffett, for example, who has a philosophy of betting on America long-term and a reputation for having a holding period of forever. You could be forgiven for becoming complacent about how long to hold a position if you listened to that advice.
» Read more about: Buffett Has Sold For 7 Quarters In a Row, What Happens Next? »
Read More
2x Champion Trader Goes SHORT
The wild statistics are flying now. At the depths of the price action on Friday, the bearish tape was as bad as any seen since the COVID lows.
2% corrections in the Dow Jones Industrial Average, NASDAQ and S&P 500 all signaled broad-based selling and the obliteration of just about every sector.
Nothing was left unscathed.
» Read more about: 2x Champion Trader Goes SHORT »
Read More
Is Tesla Breaking Out?
When CEO Elon Musk reported Tesla’s latest earnings results this week, few were excited by the numbers.
In fact, the share price immediately fell off a cliff in after-hours trading to $356 per share but within minutes a sharp bounce back occurred and, in the virtual blink of an eye, the share price was back over $400 per share.
» Read more about: Is Tesla Breaking Out? »
Read MoreThe Burst
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Spotlight
1 Social Media Stock Savvy Investors Are Watching
Reddit, often referred to as “the front page of the internet,” has a claim to fame that over 400 million monthly active users engage with it across 130,000 active communities.
There is no two ways about it, Reddit has carved out a niche in the social media landscape that is distinct from giants like Facebook and Twitter.
» Read more about: 1 Social Media Stock Savvy Investors Are Watching »
Read MoreThe Daily
Coinbase buys Deribit in $2.9 billion deal to expand crypto options base
Coinbase, the largest publicly traded cryptocurrency exchange, said on Thursday it will buy derivatives exchange Deribit in a $2.9 billion deal to expand into the crypto options markets. The move …
» Read more about: Coinbase buys Deribit in $2.9 billion deal to expand crypto options base »